KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Net Margin: 2011-2025

Historic Net Margin for Travere Therapeutics (TVTX) over the last 12 years, with Sep 2025 value amounting to 15.59%.

  • Travere Therapeutics' Net Margin rose 1575.00% to 15.59% in Q3 2025 from the same period last year, while for Sep 2025 it was -6.49%, marking a year-over-year decrease of 524.00%. This contributed to the annual value of -0.39% for FY2024, which is 18281.00% down from last year.
  • Travere Therapeutics' Net Margin amounted to 15.59% in Q3 2025, which was up 239.91% from -11.14% recorded in Q2 2025.
  • Travere Therapeutics' Net Margin's 5-year high stood at 646.92% during Q3 2023, with a 5-year trough of -739.78% in Q4 2021.
  • For the 3-year period, Travere Therapeutics' Net Margin averaged around 61.76%, with its median value being -0.16% (2024).
  • In the last 5 years, Travere Therapeutics' Net Margin spiked by 80,731bps in 2022 and then tumbled by 64,708bps in 2024.
  • Quarterly analysis of 5 years shows Travere Therapeutics' Net Margin stood at -739.78% in 2021, then soared by 80,731bps to 67.53% in 2022, then plummeted by 7,103bps to -3.50% in 2023, then spiked by 351bps to 0.01% in 2024, then surged by 1,575bps to 15.59% in 2025.
  • Its Net Margin was 15.59% in Q3 2025, compared to -11.14% in Q2 2025 and -50.44% in Q1 2025.